The goals of this Neurogenetics Center are to understand the molecular/cellular etiology and to ameliorate the course of the hereditary phakomatoses, neurofibromatosis type 2 (NF2), tuberous sclerosis (TSC) and related disorders. NF2 schwannomas can cause deafness, pain and paralysis, and meningiomas result in brain compression and occlusion of major sinuses, which are life threatening. TSC has severe manifestations including seizures, mental retardation and autism. These neurofunctional diseases share features of disrupted signaling pathways leading to abnormal neural cell development and growth due to loss of function of tumor suppressor genes. The focus of the proposed studies is on understanding genetic and cellular factors contributing to formation and progression of tumors, as well as disruption of neural development, and on generating mouse models which will allow assessment of therapeutic strategies. Project 1 (Gusella/Ramesh) - Molecular genetics of meningioma and NF-related disorders: identify additional genes and signaling pathways involved in initiation and progression of meningioma, schwannoma and related tumors, including schwannomas in schwannomatosis, and angiomyolipomas and subungual fibromas in TSC, and the role of associated proteins in cytoskeletal dynamics and abnormalities in target cells;Project 2 (Kwiatkowski) - Mouse brain models of tuberous sclerosis: create and analyze authentic brain models of TSC in conditional Tsc1 knock-out mice to gain a detailed understanding of developmental events contributing to these lesions, including role of neuroprecursor cells and response to rapamycin therapy. Project 3 (Breakefield/Sena-Esteves) - Vector query and therapy for NF2 and TSC lesions: use viral vectors to evaluate the contribution of different Tsc1-null cell types to abnormal development of the brain and to rescue a Tsc1-null neurologic phenotype by gene replacement. MicroRNA profiling of meningioma will be used to elucidate changes in concert with genomic and mRNA analyses in Project 1. Mouse models of schwannomas will be used to investigate ontogeny and treatment. These projects will be supported by Cores for Administration (Breakefield), Clinical co-ordination (Thiele/Plotkin) including clinical assessment, databases and genotype/phenotype correlations and Neuropathology and tumor banking (Stemmer-Rachamimov/Louis) ensuring reliable collection and neuropathologic assessment of human and mouse tumor/tissue samples. These cores provide a major strength to the Center in coordinating basic research and clinical investigation to facilitate translation to patient care. Collectively these studies provide a concerted effort toward understanding the genes, proteins and cells that contribute to associated tumors and malformations in the nervous system underlying neurologic deficits in NF2 and TSC for the purposes of more effective diagnosis and development of treatment paradigms.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS024279-23
Application #
8089227
Study Section
Special Emphasis Panel (ZNS1-SRB-G (08))
Program Officer
Morris, Jill A
Project Start
1997-06-01
Project End
2013-04-30
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
23
Fiscal Year
2011
Total Cost
$1,316,946
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Jordan, Justin T; Smith, Miriam J; Walker, James A et al. (2018) Pain correlates with germline mutation in schwannomatosis. Medicine (Baltimore) 97:e9717
Prabhakar, Shilpa; Zhang, Xuan; Goto, June et al. (2015) Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. Neurobiol Dis 82:22-31
Geffrey, Alexandra L; Shinnick, Julianna E; Staley, Brigid A et al. (2014) Lymphedema in tuberous sclerosis complex. Am J Med Genet A 164A:1438-42
Boronat, Susana; Shaaya, Elias A; Auladell, Maria et al. (2014) Intracranial arteriopathy in tuberous sclerosis complex. J Child Neurol 29:912-9
Di Nardo, Alessia; Wertz, Mary H; Kwiatkowski, Erica et al. (2014) Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1. Hum Mol Genet 23:3865-74
Shaaya, Elias A; Hirshberg, Jacqueline S; Rabe, Olivia T et al. (2013) Cardiac fat-containing lesions are common in tuberous sclerosis complex. Am J Med Genet A 161A:1662-5
Boronat, Susana; Van Eeghen, Agnies M; Shinnick, Julianna E et al. (2013) Stressor-related disorders in tuberous sclerosis. Ann Clin Psychiatry 25:243-9
van Eeghen, Agnies M; TerĂ¡n, Laura Ortiz; Johnson, Jason et al. (2013) The neuroanatomical phenotype of tuberous sclerosis complex: focus on radial migration lines. Neuroradiology 55:1007-1014
Prabhakar, Shilpa; Taherian, Mehran; Gianni, Davide et al. (2013) Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1. Hum Gene Ther 24:152-62
Hsieh, David T; Jennesson, Melanie M; Thiele, Elizabeth A (2013) Epileptic spasms in tuberous sclerosis complex. Epilepsy Res 106:200-10

Showing the most recent 10 out of 261 publications